This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ESLOY vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. ABT: Which Stock Is the Better Value Option?
ESLOY vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ESLOY vs. ABT: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Home Depot, JD.com and EssilorLuxottica
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, JD.com and EssilorLuxottica
EssilorLuxottica Unsponsored ADR (ESLOY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
EssilorLuxottica Unsponsored ADR (ESLOY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New Strong Sell Stocks for June 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for September 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
LabCorp's Covance Launches Laboratory Data Management Service
by Zacks Equity Research
LabCorp (LH) expands service portfolio through Covance's data management portal.
AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm
by Zacks Equity Research
AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.
Allscripts Inks Deal With Apple for Electronic Health Record
by Zacks Equity Research
Allscripts (MDRX) is working toward providing compact health records.
Omnicell's Autonomous Pharmacy to Boost Medication Management
by Zacks Equity Research
Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.
Cerus Corporation (CERS) Looks Good: Stock Adds 8.2% in Session
by Zacks Equity Research
Cerus Corporation (CERS) saw its shares rise over 8% on the day on the back of the news of a favorable regulatory development.
Graham-Cassidy Fail Shines Spotlight on 3 Top Dividend Stocks
by Zacks Equity Research
Zeroing in on dividend stocks with a solid Zacks Rank is a great way to increase the chances of beating volatile market conditions while ensuring a steady stream of cash flow. Here are three top picks in the MedTech space.